2 1 Shi Ji Jing Ji Bao Dao·2025-10-31 08:58Group 1: Health Planning and Chronic Disease Management - The National Health Commission aims to increase the average life expectancy of Chinese residents from 79 years in 2024 to around 80 years within five years, supported by chronic disease prevention efforts [1] - Chronic diseases such as cardiovascular diseases and cancer are on the rise, with over 80% of total deaths attributed to these conditions, posing significant health and economic challenges [1] - The government has integrated chronic disease prevention into national strategy, focusing on obesity management as a key area for policy intervention [3][4] Group 2: Market Dynamics and Opportunities - The obesity treatment market is becoming increasingly competitive, with major pharmaceutical companies like Novo Nordisk and Eli Lilly leading with their GLP-1 products, while domestic companies are also advancing their offerings [5][8] - The CGM market in China is projected to grow from approximately 1.7 billion yuan in 2020 to 17.9 billion yuan by 2030, indicating a strong demand for diabetes management solutions [5] - The global market for obesity and metabolic drugs is expected to exceed $100 billion by 2030, with GLP-1 drugs being a significant growth driver [5] Group 3: Distribution and Accessibility - The retail market for GLP-1 products is expanding, with companies like Novo Nordisk and Eli Lilly actively pursuing this channel due to high entry barriers in hospital settings [6] - Online channels, particularly platforms like JD Health, are becoming dominant in the weight loss drug market, accounting for over 70% of sales, significantly outpacing traditional channels [6][7] - The shift from passive to proactive health management is driving growth in home medical devices, with a notable increase in demand for self-monitoring tools [7] Group 4: Innovation and Competitive Landscape - The GLP-1 market is characterized by a "dual oligopoly" with Novo Nordisk and Eli Lilly holding significant market share, but local companies are intensifying competition through differentiated product offerings [8][9] - Domestic firms are focusing on unmet clinical needs and expanding indications to build long-term competitiveness, moving the industry from a "follower" to a "leader" position [9] - Innovations in drug delivery methods and combination therapies are being explored by local companies to enhance their market presence and address diverse patient needs [9]